LGK974: Clinical Trials

3 trials of LGK974, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 withdrawn. 2 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Completed 2
Phase 22Completed 1, Withdrawn 1

Follow LGK974: new trials by email Literature Review of LGK974 trials Research Report on LGK974

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations
WNT974, LGX818, Cetuximab - Metastatic Colorectal Cancer
Phase 1 / Phase 2CompletedArray BioPharma202014-12-012017-10-09
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
LGK974, PDR001 - Pancreatic Cancer, BRAF Mutant Colorectal Cancer
Phase 1CompletedNovartis Pharmaceuticals1852011-12-012025-06-13
A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma
WNT974 - Squamous Cell Carcinoma, Head And Neck
Phase 2WithdrawnUniversity of Michigan Rogel Cancer Center2016-09-30

Conditions studied

Colorectal Neoplasms (1)  ·  Esophageal Squamous Cell Carcinoma (1)  ·  Melanoma (1)  ·  Neoplasm Metastasis (1)  ·  Pancreatic Neoplasms (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

Array BioPharma (1)  ·  Novartis Pharmaceuticals (1)  ·  University of Michigan Rogel Cancer Center (1)

Countries

United States (3)  ·  Canada (2)  ·  France (2)  ·  Italy (2)  ·  Netherlands (2)  ·  Spain (2)  ·  Australia (1)  ·  Belgium (1)  ·  Germany (1)  ·  Israel (1)  ·  Singapore (1)

Top investigators

Francis Worden, M.D. (1)

Results publications

PMID 33941878, PMID 36811382, PMID 40578933